Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | GABBR2 | O75899 | 2/20 | 0.32 |
| ▸ | GABBR1 | Q9UBS5 | 2/20 | 0.32 |
| ▸ | LAP3 | P28838 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL787731 | 0.93 | ALDH1A1 (0.39) | PLA2G2CALDH1A1MEN1CYP1A2KMT2A | |
| Oxalic Acid SCHEMBL5022544 | 0.90 | CYP1A2 (0.39) | PLA2G2CMEN1CYP1A2KMT2AGABBR2 | |
| Oxalic Acid SCHEMBL1377851 | 0.86 | LAP3 (0.33) | GABBR2GABBR1LAP3 | |
| SCHEMBL864318 | 0.86 | CYP1A2 (0.47) | PLA2G2CMEN1CYP1A2KMT2AGABBR2 | |
| SCHEMBL9203703 | 0.84 | CYP1A2 (0.42) | PLA2G2CMEN1CYP1A2KMT2AGABBR2 | |
| SCHEMBL5841650 | 0.83 | PLA2G2C (0.43) | PLA2G2CMEN1CYP1A2KMT2AGABBR2 | |
| SCHEMBL17782328 | 0.83 | PLA2G2C (0.43) | PLA2G2CMEN1CYP1A2KMT2AGABBR2 | |
| SCHEMBL779433 | 0.78 | TRPM8 (0.45) | GABBR2GABBR1 | |
| SCHEMBL9203527 | 0.78 | ANPEP (0.40) | PLA2G2CMEN1CYP1A2KMT2AGABBR2 | |
| SCHEMBL2118428 | 0.77 | LAP3 (0.38) | MEN1CYP1A2KMT2AGABBR2GABBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9139604-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-20150025039-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. | 2015-01-22 | — | — | US | disclosed |
| US-8871785-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-20130316969-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. (US) | 2013-11-28 | — | — | US | disclosed |
| US-20110288053-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| US-8022083-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2011-09-20 | — | — | US | disclosed |
| US-20100022467-A1 | ANTI-CANCER PHOSPHONATE ANALOGS | BOOJAMRA CONSTANTINE G | 2010-01-28 | — | — | US | disclosed |
| US-20090275535-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. | 2009-11-05 | — | — | US | disclosed |
| US-20090247488-A1 | ANTI-INFLAMMATORY PHOSPHONATE COMPOUNDS | CANNIZZARO CARINA | 2009-10-01 | — | — | US | disclosed |
| US-20090227543-A1 | PHOSPHONATE COMPOUNDS HAVING IMMUNO-MODULATORY ACTIVITY | CANNIZZARO CARINA | 2009-09-10 | — | — | US | disclosed |
| EP-1620110-A2 | IMMUNOMODULATOR PHOSPHONATE CONJUGATES | GILEAD SCIENCES, INC. (US) | 2006-02-01 | — | — | EP | disclosed |
| EP-1617848-A2 | ANTI-CANCER PHOSPHONATE CONJUGATES | GILEAD SCIENCES, INC. (US) | 2006-01-25 | — | — | EP | disclosed |
| US-20050256078-A1 | Inosine monophosphate dehydrogenase inhibitory phosphonate compounds | GILEAD SCIENCES, INC. | 2005-11-17 | — | — | US | disclosed |
| US-20050215513-A1 | Use of an antiviral compound linked to one or more phosphonate groups in hepatitis C treatment; improved bioavailability, side effect reduction; antiviral compound is a 2-(2-isopropylaminothiazol-4-yl)-4-(tricyclic fused ring)-7-methoxy-quinoline compound | GILEAD SCIENCES, INC. | 2005-09-29 | — | — | US | disclosed |
| WO-2005039552-A2 | INOSINE MONOPHOSPHATE DEHYDROGENASE INHIBITORS AS PHOSPHONATE DERIVATIVES | GILEAD SCIENCES, INC. (US) | 2005-05-06 | — | — | WO | disclosed |
| WO-2004100960-A2 | ANTI-INFLAMMATORY PHOSPHONATE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2004-11-25 | — | — | WO | disclosed |
| WO-2004096286-A2 | ANTIVIRAL PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004096235-A2 | ANTI-CANCER PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004096287-A2 | INOSINE MONOPHOSPHATE DEHYDROGENASE INHIBITORY PHOSPHONATE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004096236-A2 | IMMUNOMODULATOR PHOSPHONATE CONJUGATES | GILEAD SCIENCES, INC. (US) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025039-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | TYMP, ITPA, PNP | PLA2G2C 187/4885ALDH1A1 4754/4885MEN1 3488/4885 |
| US-20110288053-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | TYMP, ITPA, PNP | PLA2G2C 187/4885ALDH1A1 4754/4885MEN1 3488/4885 |
| US-20130316969-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | TYMP, ITPA, PNP | PLA2G2C 187/4885ALDH1A1 4754/4885MEN1 3488/4885 |
| US-20090227543-A1 | PHOSPHONATE COMPOUNDS HAVING IMMUNO-MODULATORY ACTIVITY | PHOSPHO1, NFATC1, IFNG | PLA2G2C 14/4885ALDH1A1 4028/4885MEN1 3346/4885 |
| US-20090275535-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | TYMP, ITPA, PNP | PLA2G2C 187/4885ALDH1A1 4754/4885MEN1 3488/4885 |
| US-20050215513-A1 | Use of an antiviral compound linked to one or more phosphonate groups in hepatitis C treatment; improved bioavailability, side effect reduction; antiviral compound is a 2-(2-isopropylaminothiazol-4-yl)-4-(tricyclic fused ring)-7-methoxy-quinoline compound | EIF2AK2, PNP, NUDT1 | PLA2G2C 509/4885ALDH1A1 3720/4885MEN1 3872/4885 |
| US-20090247488-A1 | ANTI-INFLAMMATORY PHOSPHONATE COMPOUNDS | PHOSPHO1, TNF, PTGES | PLA2G2C 28/4885ALDH1A1 3467/4885MEN1 4122/4885 |
| US-20050256078-A1 | Inosine monophosphate dehydrogenase inhibitory phosphonate compounds | IMPDH1, IMPDH2, ITPA | PLA2G2C 808/4885ALDH1A1 312/4885MEN1 2276/4885 |
| US-20100022467-A1 | ANTI-CANCER PHOSPHONATE ANALOGS | PIK3CA, PHOSPHO1, PTEN | PLA2G2C 137/4885ALDH1A1 3678/4885MEN1 914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.